But the company hasn’t given details, and used a historical control rather than the study’s own control arm.

Now in Bristol’s hands, BMS-986442 is set to deliver its first clinical data.

Meanwhile, the RayzeBio-originated RYZ101 is back in Action.

But Imfinzi's precise setting is uncertain, and big problems loom for companies pursuing similar trials.

Roche curbs its TIGIT push, while a co-stimulation crunch could be bad news for Regeneron.

Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.